PMID- 9458099
OWN - NLM
STAT- MEDLINE
DCOM- 19980224
LR  - 20231213
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 58
IP  - 3
DP  - 1998 Feb 1
TI  - Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal 
      individuals and colorectal cancer patients.
PG  - 512-8
AB  - The effect of doses of the secretor (Se) and Lewis (Le) genes on the serum levels 
      of CA19-9 and DU-PAN-2 was investigated in 400 normal individuals. It was clearly 
      demonstrated that the Se gene dosage negatively affected both the CA19-9 and 
      DU-PAN-2 values, whereas the Le gene dosage positively affected the CA19-9 value 
      and negatively affected the DU-PAN-2 value. The 400 normal individuals were 
      separated into nine groups by their Le and Se genotypes, as follows: group 1, 
      Le/Le and se/se; group 2, Le/le and se/se; group 3, Le/Le and Se/se; group 4, 
      Le/le and Se/se; group 5, Le/Le and Se/Se; group 6, Le/le and Se/Se; group 7, 
      le/le and se/se; group 8, le/le and Se/se; and group 9, le/le and Se/Se. The 
      group 1 individuals, having homozygous inactive Se alleles (se/se) and homozygous 
      active Le alleles (Le/Le), exhibited the highest mean CA19-9 value. The CA19-9 
      value clearly ranged from a high in group 1 to a low in group 9. All of the 
      Le-negative individuals who had the le/le genotype (groups 7, 8, and 9) had 
      completely negative CA19-9 values, i.e., under 1.0 unit/ml, irrespective of the 
      Se genotype. Group 7 individuals (le/le and se/se) showed a higher mean DU-PAN-2 
      value than did individuals in other groups. The Le-negative individuals in groups 
      8 and 9 also showed a higher mean DU-PAN-2 value than did the Le-positive 
      individuals in groups 1-6. We recommend that the revised Le and Se 
      genotype-dependent positive/negative cutoff values for CA19-9 and DU-PAN-2, 
      determined in this study, be applied for more accurate cancer diagnoses. The Le 
      and Se genotypes of 168 patients with colorectal cancer were also examined, and 
      the CA19-9 and DU-PAN-2 values were measured before surgical resection. All 15 
      Le-negative patients (le/le) with colorectal cancer again showed undetectable 
      CA19-9 values, i.e., under 1.0 unit/ml, but many of them exhibited highly 
      positive DU-PAN-2 values. In contrast, many of the Le-positive patients (Le/Le or 
      Le/le) had positive CA19-9 values, whereas very few of them exhibited positive 
      DU-PAN-2 values. CA19-9 measurement is more useful than is DU-PAN-2 measurement 
      for Le-positive patients, but it is not useful for Le-negative ones. DU-PAN-2 
      measurement should be performed in Le-negative patients for cancer diagnosis.
FAU - Narimatsu, H
AU  - Narimatsu H
AD  - Division of Cell Biology, Institute of Life Science, Soka University, Hachioji, 
      Toyko, Japan. hisashi@scc1.t.soka.ac.jp
FAU - Iwasaki, H
AU  - Iwasaki H
FAU - Nakayama, F
AU  - Nakayama F
FAU - Ikehara, Y
AU  - Ikehara Y
FAU - Kudo, T
AU  - Kudo T
FAU - Nishihara, S
AU  - Nishihara S
FAU - Sugano, K
AU  - Sugano K
FAU - Okura, H
AU  - Okura H
FAU - Fujita, S
AU  - Fujita S
FAU - Hirohashi, S
AU  - Hirohashi S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CA-19-9 Antigen)
RN  - 0 (DU-PAN-2 antigen, human)
RN  - 0 (Epitopes)
RN  - 0 (Neoplasm Proteins)
RN  - EC 2.4.1.- (Fucosyltransferases)
RN  - EC 2.4.1.65 (3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase)
SB  - IM
MH  - Alleles
MH  - Antigens, Neoplasm/*blood/metabolism
MH  - Biomarkers, Tumor/*blood/metabolism
MH  - CA-19-9 Antigen/*blood/metabolism
MH  - Carbohydrate Sequence
MH  - Colorectal Neoplasms/*blood/genetics
MH  - Epitopes/genetics/metabolism
MH  - Fucosyltransferases/*genetics
MH  - Gene Dosage
MH  - Genotype
MH  - Glycosylation
MH  - Humans
MH  - Molecular Sequence Data
MH  - Neoplasm Proteins/*blood/metabolism
MH  - Phenotype
MH  - Protein Processing, Post-Translational/*genetics
MH  - Galactoside 2-alpha-L-fucosyltransferase
EDAT- 1998/02/11 00:00
MHDA- 1998/02/11 00:01
CRDT- 1998/02/11 00:00
PHST- 1998/02/11 00:00 [pubmed]
PHST- 1998/02/11 00:01 [medline]
PHST- 1998/02/11 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1998 Feb 1;58(3):512-8.